Zobrazeno 1 - 10
of 111
pro vyhledávání: '"B. van der Hiel"'
Autor:
A. Zwanenburg, W. Van Houdt, M. Schrijver, B. Van der Hiel, B. Seinstra, W. Schreuder, M. Wouters, E. Plasmeijer
Publikováno v:
EJC Skin Cancer, Vol 2, Iss , Pp 100043- (2024)
Externí odkaz:
https://doaj.org/article/b50031f0eac5485f881058f2cd167f21
Autor:
Danique Giesen, E. L. van der Veen, J.B.A.G. Haanen, A. J. van der Wekken, Derk Jan A. de Groot, Lucie Hijmering-Kappelle, Mathilde Jalving, P P van de Donk, H.J.M. Groen, M. N. Lub-de Hooge, Adrienne H. Brouwers, E.G.E. de Vries, Wim Timens, Iris C. Kok, B. van der Hiel, W Uyterlinde, Sjoerd G. Elias, G.A.P. (Geke) Hospers, J A Hooiveld, Thijo J N Hiltermann
Publikováno v:
Annals of Oncology, 33(1), 80-88. Oxford University Press
Annals of Oncology
Annals of Oncology
Background: Programmed cell death protein 1 (PD-1) antibody treatment is standard of care for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients will benefit is currently not possible. Tumor uptake and biodistributi
Autor:
A.C.J. van Akkooi, B.A. van de Wiel, B. van der Hiel, Yvonne Schrage, Michel W.J.M. Wouters, Emma H. A. Stahlie, Annemarie Bruining, W.J. van Houdt
Publikováno v:
European Journal of Surgical Oncology. 47:1157-1162
Background Stage IIB/IIC (8th AJCC) melanoma patients are known to have high-risk primary tumors, however they follow the same routine to sentinel lymph node biopsy (SLNB) as more low risk tumors. Guidelines are not conclusive regarding the use of pr
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
E H A, Stahlie, B, van der Hiel, A, Bruining, B, van de Wiel, Y M, Schrage, M W J M, Wouters, W J, van Houdt, A C J, van Akkooi
Publikováno v:
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 47(5)
Stage IIB/IIC (8th AJCC) melanoma patients are known to have high-risk primary tumors, however they follow the same routine to sentinel lymph node biopsy (SLNB) as more low risk tumors. Guidelines are not conclusive regarding the use of preoperative
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Johannes J. Bonenkamp, H. J. Hoekstra, Senada Koljenović, C. M. C. Oude Ophuis, B.A. van de Wiel, A.C.J. van Akkooi, B. van der Hiel, J.H.W. de Wilt, J. van Wissen, Cees Verhoef, M. G. Niebling, Dirk J. Grünhagen
Publikováno v:
Annals of Surgical Oncology, 22 Suppl 3, pp. 1172-80
Annals of Surgical Oncology, S1172-S1180. Springer New York
STARTPAGE=S1172;ENDPAGE=S1180;ISSN=1068-9265;TITLE=Annals of Surgical Oncology
Annals of Surgical Oncology, 22 Suppl 3, 1172-80
Annals of Surgical Oncology, 22 Suppl 3, S1172-80. Springer New York
Annals of Surgical Oncology, S1172-S1180. Springer New York
STARTPAGE=S1172;ENDPAGE=S1180;ISSN=1068-9265;TITLE=Annals of Surgical Oncology
Annals of Surgical Oncology, 22 Suppl 3, 1172-80
Annals of Surgical Oncology, 22 Suppl 3, S1172-80. Springer New York
Contains fulltext : 152676.pdf (Publisher’s version ) (Open Access) BACKGROUND: Patients with palpable melanoma groin metastases have a poor prognosis. There is debate whether a combined superficial and deep groin dissection (CGD) is necessary or i
Autor:
B.A. van de Wiel, Emma H. A. Stahlie, Viola Franke, Yvonne Schrage, L. Zuur, M. Klop, B. van der Hiel, A.C.J. van Akkooi, W.J. van Houdt, Michel W.J.M. Wouters
Publikováno v:
Annals of Oncology. 31:S750
Autor:
B.A. van de Wiel, A.C.J. van Akkooi, Daniel S. Peeper, Max J. Lahaye, M. Klop, B. van der Hiel, Stephanie A. Blankenstein, Karolina Sikorska, Maartje W. Rohaan, J.B.A.G. Haanen, A. Sari
Publikováno v:
Annals of Oncology. 31:S743
Autor:
Emma H. A. Stahlie, Viola Franke, Willem M.C. Klop, A.C.J. van Akkooi, B.A. van de Wiel, Michel W.J.M. Wouters, Danique M.S. Berger, B. van der Hiel, L. Zuur, W.J. van Houdt
Publikováno v:
Annals of Oncology. 30:v547
Background Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1 (HSV-1), which can be administered intralesionally in patients with stage IIIB/C-IVM1a unresectable melanoma. When surgery is not a treatment option in the head an